Therapeutic potential of CD20 x CD3 bispecific antibodies

FHS
April 5, 2024
5:24 am

On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials.

Shift Bioscience raises $16 M to advance cell simulation AI platform

Shift Bioscience is a biotech company using generative AI models to understand how activation of different genes can reverse the aging process. This research is

October 16, 2024

Opinion | From Salad Roulette to Salmonella in Poultry and Peanuts

Panosian Dunavan is an infectious diseases expert. In August 2006, Ruby Trautz of Omaha, Nebraska was the first person of several to die in a

August 18, 2023

Hospitalizations With Fake Ozempic; Vosoritide OK’d for All Ages; Mounjaro for Kids?

Law enforcement and public health officials say a surge in counterfeit versions of drugs that help with weight loss like semaglutide (Ozempic, Wegovy) may be

October 25, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.